Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
41.75
+0.19 (0.46%)
At close: Aug 7, 2026, 4:00 PM EDT
41.71
-0.04 (-0.10%)
After-hours: Aug 7, 2026, 7:34 PM EDT

Celldex Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3,2751,8071,6772,2162,1041,806
Market Cap Growth
130.10%7.76%-24.32%5.35%16.51%160.23%
Enterprise Value
2,5631,292956.761,7991,8041,402
Last Close Price
41.7527.1625.2739.6644.5738.64
PS Ratio
20730.801169.89238.93322.00892.55388.23
PB Ratio
4.583.432.255.166.454.30
P/TBV Ratio
4.213.612.264.786.994.22
EV/Sales Ratio
16220.15836.55136.29261.41765.30301.44
Debt / Equity Ratio
0.000.000.000.000.010.00
Net Debt / Equity Ratio
-1.00-0.98-0.96-0.97-0.92-0.96
Net Debt / EBITDA Ratio
2.211.813.762.752.675.92
Net Debt / FCF Ratio
2.942.414.513.822.846.49
Asset Turnover
0.000.000.010.020.010.01
Quick Ratio
11.7110.2118.3813.6916.4124.71
Current Ratio
11.8210.4918.9113.8717.0724.86
Return on Equity (ROE)
-48.41%-40.62%-26.84%-37.45%-30.13%-22.43%
Return on Assets (ROA)
-47.73%-41.79%-31.01%-37.77%-28.90%-20.87%
Return on Invested Capital (ROIC)
-5915.00%-1487.52%-1011.24%-805.37%-547.47%-377.64%
Return on Capital Employed (ROCE)
-52.01%-44.73%-32.86%-40.21%-30.24%-21.93%
Buyback Yield / Dilution
-4.49%-3.15%-32.91%-3.33%-9.37%-44.64%
Total Shareholder Return
-4.49%-3.15%-32.91%-3.33%-9.37%-44.64%
SEC Filings: 10-K · 10-Q